359 related articles for article (PubMed ID: 31264169)
1. Discovery and preclinical characterization of [
Kroth H; Oden F; Molette J; Schieferstein H; Capotosti F; Mueller A; Berndt M; Schmitt-Willich H; Darmency V; Gabellieri E; Boudou C; Juergens T; Varisco Y; Vokali E; Hickman DT; Tamagnan G; Pfeifer A; Dinkelborg L; Muhs A; Stephens A
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2178-2189. PubMed ID: 31264169
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-(4-(2-fluoroethoxy)piperidin-1-yl)-9-methyl-9H-pyrrolo[2,3-b:4,5-c']dipyridine ([18F]PI-2014) as PET tracer for the detection of pathological aggregated tau in Alzheimer's disease and other tauopathies.
Gabellieri E; Capotosti F; Molette J; Sreenivasachary N; Mueller A; Berndt M; Schieferstein H; Juergens T; Varisco Y; Oden F; Schmitt-Willich H; Hickman D; Dinkelborg L; Stephens A; Pfeifer A; Kroth H
Eur J Med Chem; 2020 Oct; 204():112615. PubMed ID: 32771872
[TBL] [Abstract][Full Text] [Related]
3.
Kroth H; Oden F; Molette J; Schieferstein H; Gabellieri E; Mueller A; Berndt M; Sreenivasachary N; Serra AM; Capotosti F; Schmitt-Willich H; Hickman D; Pfeifer A; Dinkelborg L; Stephens A
J Med Chem; 2021 Sep; 64(17):12808-12830. PubMed ID: 34455780
[TBL] [Abstract][Full Text] [Related]
4. [
Sanabria Bohórquez S; Marik J; Ogasawara A; Tinianow JN; Gill HS; Barret O; Tamagnan G; Alagille D; Ayalon G; Manser P; Bengtsson T; Ward M; Williams SP; Kerchner GA; Seibyl JP; Marek K; Weimer RM
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2077-2089. PubMed ID: 31254035
[TBL] [Abstract][Full Text] [Related]
5. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue.
Aguero C; Dhaynaut M; Normandin MD; Amaral AC; Guehl NJ; Neelamegam R; Marquie M; Johnson KA; El Fakhri G; Frosch MP; Gomez-Isla T
Acta Neuropathol Commun; 2019 Mar; 7(1):37. PubMed ID: 30857558
[TBL] [Abstract][Full Text] [Related]
6. Monoamine oxidase B inhibitor, selegiline, reduces
Ng KP; Pascoal TA; Mathotaarachchi S; Therriault J; Kang MS; Shin M; Guiot MC; Guo Q; Harada R; Comley RA; Massarweh G; Soucy JP; Okamura N; Gauthier S; Rosa-Neto P
Alzheimers Res Ther; 2017 Mar; 9(1):25. PubMed ID: 28359327
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of
Declercq L; Rombouts F; Koole M; Fierens K; Mariën J; Langlois X; Andrés JI; Schmidt M; Macdonald G; Moechars D; Vanduffel W; Tousseyn T; Vandenberghe R; Van Laere K; Verbruggen A; Bormans G
J Nucl Med; 2017 Jun; 58(6):975-981. PubMed ID: 28232614
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of [
Aguero C; Dhaynaut M; Amaral AC; Moon SH; Neelamegam R; Scapellato M; Carazo-Casas C; Kumar S; El Fakhri G; Johnson K; Frosch MP; Normandin MD; Gómez-Isla T
Acta Neuropathol; 2024 Jan; 147(1):25. PubMed ID: 38280071
[TBL] [Abstract][Full Text] [Related]
9. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD
Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172
[TBL] [Abstract][Full Text] [Related]
10. Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351.
Oh M; Oh SJ; Lee SJ; Oh JS; Roh JH; Chung SJ; Lee JH; Lee CS; Kim JS
Clin Nucl Med; 2020 Nov; 45(11):841-847. PubMed ID: 32910050
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship around PI-2620 highlights the importance of the nitrogen atom position in the tricyclic core.
Kroth H; Oden F; Serra AM; Molette J; Mueller A; Berndt M; Capotosti F; Gabellieri E; Schmitt-Willich H; Hickman D; Pfeifer A; Dinkelborg L; Stephens A
Bioorg Med Chem; 2021 Dec; 52():116528. PubMed ID: 34839158
[TBL] [Abstract][Full Text] [Related]
13. Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [
Ng KP; Therriault J; Kang MS; Struyfs H; Pascoal TA; Mathotaarachchi S; Shin M; Benedet AL; Massarweh G; Soucy JP; Rosa-Neto P; Gauthier S
Neuroimage Clin; 2019; 24():102091. PubMed ID: 31795034
[TBL] [Abstract][Full Text] [Related]
14. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879
[TBL] [Abstract][Full Text] [Related]
15. Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease.
Tago T; Furumoto S; Okamura N; Harada R; Adachi H; Ishikawa Y; Yanai K; Iwata R; Kudo Y
J Nucl Med; 2016 Apr; 57(4):608-14. PubMed ID: 26697966
[TBL] [Abstract][Full Text] [Related]
16. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection.
Fawaz MV; Brooks AF; Rodnick ME; Carpenter GM; Shao X; Desmond TJ; Sherman P; Quesada CA; Hockley BG; Kilbourn MR; Albin RL; Frey KA; Scott PJ
ACS Chem Neurosci; 2014 Aug; 5(8):718-30. PubMed ID: 24896980
[TBL] [Abstract][Full Text] [Related]
17. Multicenter
Rullmann M; Brendel M; Schroeter ML; Saur D; Levin J; Perneczky RG; Tiepolt S; Patt M; Mueller A; Villemagne VL; Classen J; Stephens AW; Sabri O; Barthel H; On Behalf Of The German Imaging Initiative For Tauopathies Gii T
Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327650
[TBL] [Abstract][Full Text] [Related]
18. Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy.
Murugan NA; Nordberg A; Ågren H
ACS Chem Neurosci; 2021 Jul; 12(13):2437-2447. PubMed ID: 34152739
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Characterization of the Tau PET Tracer [
Harada R; Lerdsirisuk P; Shimizu Y; Yokoyama Y; Du Y; Kudo K; Ezura M; Ishikawa Y; Iwata R; Shidahara M; Ishiki A; Kikuchi A; Hatano Y; Ishihara T; Onodera O; Iwasaki Y; Yoshida M; Taki Y; Arai H; Kudo Y; Yanai K; Furumoto S; Okamura N
J Nucl Med; 2023 Sep; 64(9):1495-1501. PubMed ID: 37321821
[TBL] [Abstract][Full Text] [Related]
20. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging.
Murugan NA; Chiotis K; Rodriguez-Vieitez E; Lemoine L; Ågren H; Nordberg A
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1369-1382. PubMed ID: 30919054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
